Independent and Incremental Value of ECG Markers for Prediction of Cancer Therapy‐Related Cardiac Dysfunction
Open Access
- 20 May 2025
- journal article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (10) , e039203
Abstract
Background: Strategies to estimate risk of cancer therapy‐related cardiac dysfunction (CTRCD) before initiating cardiotoxic cancer treatment are needed. We hypothesized that baseline ECG markers could identify patients at risk for CTRCD. Methods and Results: In this retrospective cohort study, 1278 female patients with stage I–III HER2 (human epidermal growth factor receptor 2)‐positive breast cancer meeting the following inclusion criteria were included: baseline ECG with QRS P P <0.001, likelihood ratio test) with continuous net reclassification improvement of 34.9% and integrated discrimination improvement of 3.4%. Conclusions: Baseline ECG variables are predictive of subsequent CTRCD and provide incremental value to established clinical risk factors for CTRCD risk classification.Keywords
This publication has 31 references indexed in Scilit:
- Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast CancerJAMA Oncology, 2020
- Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyEuropean Journal of Heart Failure, 2020
- Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast CancerJAMA Cardiology, 2020
- Association Between Electrocardiographic and Echocardiographic Markers of Stage B Heart Failure and Cardiovascular OutcomeESC Heart Failure, 2017
- Angiotensin II–Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast CancerJAMA Oncology, 2016
- Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast CancerJAMA Oncology, 2016
- Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancerBreast Cancer Research and Treatment, 2015
- Usefulness of Quantitative Assessment of Electrocardiographic ST Depression for Predicting New-Onset Heart Failure in American Indians (from the Strong Heart Study)The American Journal of Cardiology, 2007
- Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyondStatistics in Medicine, 2007
- Major and Minor ECG Abnormalities in Asymptomatic Women and Risk of Cardiovascular Events and MortalityJAMA, 2007